Back to Search
Start Over
Antivirals for COVID-19: A critical review
- Source :
- Clinical Epidemiology and Global Health, Vol 9, Iss, Pp 90-98 (2021), Clinical Epidemiology and Global Health
- Publication Year :
- 2021
- Publisher :
- Elsevier, 2021.
-
Abstract
- No specific drugs have been approved for coronavirus disease 2019 (COVID-19) to date as the development of antivirals usually requires time. Therefore, assessment and use of currently available antiviral drugs is critical for a timely response to the current pandemic. Here, we have reviewed anti-SARS-CoV-2 potencies of available antiviral drug groups such as fusion inhibitors, protease inhibitors, neuraminidase inhibitors, and M2 ion-channel protein blockers. Although clinical trials to assess the efficacy of these antivirals are ongoing, this review highlights important information including docking and modeling analyses, in vitro studies, as well as results from clinical uses of these antivirals against COVID-19 pandemic.
- Subjects :
- Microbiology (medical)
2019-20 coronavirus outbreak
Coronavirus disease 2019 (COVID-19)
Epidemiology
medicine.drug_class
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
Review Article
medicine.disease_cause
Bioinformatics
03 medical and health sciences
0302 clinical medicine
Pandemic
medicine
030212 general & internal medicine
Antiviral
Coronavirus
030219 obstetrics & reproductive medicine
biology
business.industry
SARS-CoV-2
Public Health, Environmental and Occupational Health
COVID-19
Clinical trial
Infectious Diseases
biology.protein
Antiviral drug
Public aspects of medicine
RA1-1270
business
Neuraminidase
Subjects
Details
- Language :
- English
- ISSN :
- 22133984
- Volume :
- 9
- Database :
- OpenAIRE
- Journal :
- Clinical Epidemiology and Global Health
- Accession number :
- edsair.doi.dedup.....8f8628d371f718cdaea1745397eacc28